Progestogen-Only Oral Contraception With Dose-Tuned Ovulation Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Progestogen-only pills (POP) have limited acceptability due to high failure rates, irregular bleeding, and hypoestrogenic or androgenic side effects, limiting their use as a viable contraceptive option.
Innovation Solution
A new POP regimen using 0.110 mg to 0.150 mg of levonorgestrel (LNG) or 0.220 mg to 0.300 mg of norgestrel (NG) administered once daily, without additional hormones, to achieve high contraceptive efficacy, acceptable bleeding patterns, and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of progestogen are used to improve contraceptive efficacy, then ovulation inhibition is enhanced, but hypoestrogenic side effects and androgenic side effects increase
Solution Approach 1:
The patent applies parameter changes by precisely optimizing the progestogen dosage to a specific range (0.110-0.150 mg LNG or 0.220-0.300 mg NG daily) that achieves complete ovulation inhibition while minimizing hypoestrogenic and androgenic side effects. This dosage optimization represents a critical parameter adjustment that resolves the contradiction between efficacy and side effects
Solution Approach 2:
The patent introduces estradiol monitoring as an intermediary parameter to guide dosing decisions. By maintaining estradiol levels within a specific range (greater than 120 pmol/L), the patent uses this hormonal marker as a mediator to balance ovulation inhibition effectiveness with prevention of hypoestrogenic side effects
2Object-generated harmful factors
If lower doses of progestogen are used to reduce side effects, then hypoestrogenic effects are minimized, but contraceptive failure rate increases
Solution Approach 1:
The patent establishes a minimum effective dosage threshold (0.110 mg LNG or 0.220 mg NG daily) through parameter optimization. This dosage represents the critical lower bound that simultaneously prevents both contraceptive failure and hypoestrogenic side effects, resolving the contradiction between safety and efficacy
3Object-affected harmful factors
If progestogen-only pills are used to avoid thrombosis risk, then thrombotic events are reduced, but contraceptive efficacy is lower compared to combined oral contraceptives
Solution Approach 1:
The patent achieves a breakthrough by optimizing the progestogen dosage parameter to a level (0.110-0.150 mg LNG or 0.220-0.300 mg NG daily) that provides contraceptive efficacy comparable to or exceeding combined oral contraceptives, while maintaining the thrombosis safety advantage of progestogen-only formulations
4Object-generated harmful factors
If irregular bleeding is managed by extending pill breaks, then bleeding patterns are modified, but contraceptive efficacy is reduced
Solution Approach 1:
The patent resolves the bleeding issue through parameter optimization by selecting a dosage (0.110-0.150 mg LNG or 0.220-0.300 mg NG daily) that maintains endometrial stability and produces acceptable bleeding patterns without requiring extended pill breaks, thereby preserving continuous contraceptive protection
Data Source
AI summary
A method for providing progestogen only contraception. The method includes the step of orally administering once a day to a subject desiring contraception a dosage form comprising about 0.125 mg to about 0.145 mg of levonorgestrel (LNG) and at least one pharmaceutically acceptable excipient for a period of at least 23 to 30 days or longer.